Fly News Breaks for March 6, 2015
WX
Mar 6, 2015 | 05:38 EDT
Goldman Sachs downgraded WuXi PharmaTech to Neutral from Conviction Buy citing the outperformance of shares and the company's higher than expected capital expenditure guidance for 2015. Goldman also cut its price target for shares to $39.50 from $44.50 following Wuxi's Q4 results.
News For WX From the Last 2 Days
There are no results for your query WX